Fosun, which holds a 57.86% stake in Gland Pharma, according to exchange data, did not immediately respond to Reuters' request for comment. Gland Pharma declined to comment.
(Reporting by Nandan Mandayam in Bengaluru; Editing by Savio D'Souza)
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
23.19 CNY | +1.35% | +3.02% | -7.35% |
24/04 | Fosun Pharma Unit Gets Marketing Registration Approval for Tuberculosis Drug from Chinese Regulator | MT |
18/04 | China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy | MT |
BENGALURU (Reuters) - China's Shanghai Fosun Pharmaceutical Group Co Ltd is considering a sale of Indian drugmaker Gland Pharma Ltd, which has a market value of $3.5 billion, Bloomberg reported, citing people familiar with the matter.
Fosun, which holds a 57.86% stake in Gland Pharma, according to exchange data, did not immediately respond to Reuters' request for comment. Gland Pharma declined to comment.
(Reporting by Nandan Mandayam in Bengaluru; Editing by Savio D'Souza)
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
1,709 INR | -1.10% | -3.76% | 3.41B | ||
23.19 CNY | +1.35% | +3.02% | 7.65B | ||
1st Jan change | Capi. | |
---|---|---|
-7.35% | 7.65B | |
+25.83% | 661B | |
+26.79% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+14.02% | 231B | |
+4.67% | 200B | |
-9.41% | 195B | |
-6.26% | 145B |